Bioactivity assays demonstrated that several of these compounds exhibit notable inhibitory effects against PTP1B, an important therapeutic target for type 2 diabetes and obesity. The gene discussed is PTPN1; the disease is obesity due to melanocortin 4 receptor deficiency.